Referred Tests
Advancing the
diagnosis
Testing for the full spectrum of hematologic disorders
Our comprehensive test menu has been
created to aid in diagnosis and treatment
selection across the full spectrum of hematologic
disorders. Through our clinical experience, we
have developed and validated practice-based,
data-driven algorithms that improve patient care, increase efficiency, and reduce costs.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly hematology testing newsletter.
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
1 million
hematology and hematopathology tests performed annually
70+
hematologists and hematopathologists on staff at Mayo Clinic
31
hematology-focused algorithms to guide test ordering
24/7
support from Mayo Clinic physicians and scientists
Innovation and collaboration between experts
Our laboratories are led by board-certified hematopathologists who focus on molecular diagnostics and prognostics of hematologic disorders, reviewing cases to provide interpretation of results related to clinically relevant genes. These experts are on call 24/7, so they are available any time you need answers.
The right test
at the right time
More than 30 hematology-focused algorithms are integrated directly into our testing approaches to ensure the right tests are being ordered at the right time. This approach simplifies the ordering process, arriving at clinically actionable answers for your patients, faster.
Unparalleled service
Our testing is supported by a round-the-clock staff of expert laboratory directors and genetic counselors who assist with everything from test ordering to results interpretation. Our experts collaborate closely with clients, not only to reach the right answers for current patients, but also to guide the development of future testing.
A Case-Based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis
Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and literature, we will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.
The latest
On Oct. 6‒8, 2021, Mayo Clinic Laboratories is hosting its 17th Bleeding and Thrombosing Diseases Conference and Workshop, and on Oct. 8-9, 2021, we’re also hosting a Non-Malignant Hematology Conference. Both conferences will be held in-person in Rochester, Minnesota, and also live-streamed online.
For patients with chronic lymphocytic leukemia (CLL) — the most common leukemia in adults — advanced testing can not only provide valuable information about their disease state, but peace of mind in the face of a progressive, incurable illness. Oftentimes, however, complex molecular and genetic tests to identify biomarker cues about disease trajectory and treatment intolerance are not performed, putting patients at risk for unmet expectations and unsatisfactory outcomes.
Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to confirm diagnosis and direct care.
PACE / State of CA / State of FL
In this month’s “Virtual Lecture,” Justin Kreuter, M.D., goes over the importance of maintaining a healthy blood donor community by talking about the effects of blood donation on stored iron and describing which individuals are at a higher risk for iron deficiency anemia.
The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.